Trial Profile
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors PTC Therapeutics
- 04 Feb 2021 According to a PTC Therapeutics media release, company will host a conference call today at 5:30 p.m. E.T. to review results from this study.
- 26 Jan 2021 Status changed from active, no longer recruiting to completed.
- 09 Dec 2020 According to a PTC Therapeutics media release, data from the study is expected in Q1 2021.